Here the authors show that reduction of Foxf2 expression in stromal cells is associated with high grade prostate cancer and that increasing prostatic stromal Foxf2 sensitizes prostate cancer to immune checkpoint blockade. This evidence concerns the gene FOXF2 and prostate carcinoma.